Gene and Protein Expression Profiles After Treatment of Actinic Keratoses (PACKS)
Actinic Keratoses
About this trial
This is an interventional treatment trial for Actinic Keratoses
Eligibility Criteria
Inclusion Criteria: Participants should have a clinical diagnosis of actinic keratosis Participants should be 18 years old or above Participants must sign an informed consent Exclusion Criteria: Known allergic reaction to either 5-fluorouracil , imiquimod, or melatonin Immunomodulating treatment Predictable poor compliance (due to i.e. dementia, substance abuse, psychiatric disease, life-threatening disease or language barriers) Pregnant or breastfeeding Females not in menopause (defined as no menstruation during the last 12 months) should use a secure birth control (intrauterine devices, hormonal contraceptives including - oral pills, patches, vaginal rings and injections) during the entire period of the trial
Sites / Locations
- Zealand University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Experimental
No Intervention
5-Fluorouracil
Imiquimod
Melatonin
Control
Patients will be asked apply a 40 mg/g creme containing 5-Fluorouracil once a day on their lesion for 10 days. A biopsy will be taken four days after last application. The patient will be refered to a dermatologist for further treatment, if necessary.
Patients will be asked apply a 50 mg/g creme containing imiquimod thrice a week on their lesion for 10 days. A biopsy will be taken four days after last application. The patient will be refered to a dermatologist for further treatment, if necessary.
Patients will be asked apply a 25 mg/g creme containing melatonin once a day on their lesion for 10 days. A biopsy will be taken four days after last application. The patient will be refered to a dermatologist for further treatment, if necessary.
A biopsy will be taken from the patient and the patient will be refered to a dermatologist for further treatment, if necessary.